Application of Xiaoxiao decoction in preparation of medicine for treating atherosclerosis

By constructing a mouse atherosclerosis model, the effects of Xiaoxianxiong Decoction on atherosclerosis were studied. It was found that it can improve aortic plaque and thickening, improve liver tissue structure, reduce the level of specific lipids in serum, and increase the level of specific enzymes. This solves the problem of the lack of scientific evidence for the application of Xiaoxianxiong Decoction in the treatment of atherosclerosis and provides a scientific basis for its clinical application.

CN119033871AInactive Publication Date: 2024-11-29SHAANXI ACAD OF TRADITIONAL CHINESE MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411318965.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-21
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There are no reports on the therapeutic effects of Xiaoxianxiong Decoction on atherosclerosis in the current technology, and there is a lack of scientific evidence.

Method used

By constructing an experimental mouse model of atherosclerosis, this study investigated the effects of Xiaoxianxiong Decoction on body weight, arterial lipid plaques, liver lipid plaques, serum lipids, and levels of MDA, SOD, GSH-Px, and GR in atherosclerotic mice. The mechanism by which Xiaoxianxiong Decoction treats atherosclerosis was explored. The specific components include Coptis chinensis, Pinellia ternata, and Trichosanthes kilograms of fruit, with a dosage of 3.139-12.558 g per kilogram of body weight.

Benefits of technology

Xiao Xianxiong Decoction exerts its therapeutic effect on atherosclerosis by improving aortic plaque and thickening, improving liver tissue structure, reducing serum L-LDL, TC and TG levels, increasing H-LDL levels, reducing aortic MDA levels, and increasing SOD, GSH-Px and GR levels, providing a scientific basis for clinical application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033871A_ABST
    Figure CN119033871A_ABST
Patent Text Reader

Abstract

The invention discloses application of Xiaoxiao decoction in preparation of a medicine for treating atherosclerosis, and belongs to the technical field of traditional Chinese medicines. By constructing an AS model of an experimental mouse and researching the treatment effect and the corresponding action mechanism of the the levels of SOD, GSH-Px and GR of aorta are increased, and the effect of treating atherosclerosis can be achieved. The research finds that a scientific basis is provided for the clinical application of the Xiaoxiao decoction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicine, and in particular to application of Xiaoxianxiong decoction in preparing a medicine for treating atherosclerosis. Background Art

[0002] Atherosclerosis (AS) is a chronic inflammatory disease that can lead to the occurrence of coronary artery disease and death. It is the pathological basis of many serious cardiovascular diseases such as ischemic heart disease, myocardial infarction, and stroke, which seriously endangers human health. The main therapeutic drugs currently used in clinical practice are: statins that regulate blood lipids, antiplatelet aggregation drugs, vasodilators, and anticoagulant and thrombolytic drugs. These drugs have clear therapeutic effects, but are often accompanied by obvious side effects. In recent years, traditional Chinese medicine has played an increasingly important role in the treatment of AS.

[0003] Xiao Xian Xiong Tang, from Zhang Zhongjing's Treatise on Febrile Diseases in the Eastern Han Dynasty, consists of one liang of Coptis chinensis, half a liter of Pinellia ternata, and one large piece of Trichosanthes fruit. It has the effects of clearing heat and resolving phlegm, widening the chest and dispersing nodules, and is a representative prescription for treating phlegm-heat syndrome. Trichosanthes fruit is the main ingredient in the prescription, clearing heat and resolving phlegm, and relieving chest numbness; Coptis chinensis is the secondary ingredient, purging heat and reducing fire, and removing the heart-stomach pain; Pinellia ternata is used to reduce adverse reactions and eliminate nodules, and remove the heart-stomach pain; Pinellia ternata and Coptis chinensis are used together, one is pungent and the other is bitter, and the pungent effect can open up the stomach and the bitter effect can lower the stomach. Together with Trichosanthes fruit, it has the benefits of clearing heat and dissolving phlegm, dispersing nodules and dispersing nodules. In recent years, this prescription has been widely used in the treatment of cardiovascular diseases such as coronary heart disease, hypertension, hyperlipidemia, and acute myocardial infarction, with significant efficacy.

[0004] However, the therapeutic effect of Xiaoxianxiong Decoction in atherosclerosis has not been reported yet. Summary of the invention

[0005] In view of the above-mentioned problems, the present invention aims to provide an application of Xiaoxianxiong Decoction in the preparation of a medicament for treating atherosclerosis. By constructing an experimental mouse AS model, the effects of Xiaoxianxiong Decoction on the body weight of AS mice, the effects on arterial lipid plaques and pathological structures, the effects on liver lipid plaques and pathological structures, the effects on serum blood lipids, and the levels of aortic MDA, SOD, GSH-Px and GR are studied. The mechanism by which Xiaoxianxiong Decoction plays a role in treating atherosclerosis is explored, providing a scientific basis for the clinical application of Xiaoxianxiong Decoction.

[0006] In order to achieve the above-mentioned object, the present invention provides, on one hand, the use of Xiaoxianxiong Decoction in the preparation of a medicine for treating atherosclerosis.

[0007] Specifically, the components of the Xiao Xianxiong Decoction include Coptis chinensis, Pinellia ternata and Trichosanthes fruit.

[0008] Specifically, Xiao Xianxiong Decoction plays a role in treating atherosclerosis by improving aortic plaques and aortic thickening, improving liver tissue structure, inhibiting liver lipid accumulation, reducing serum L-LDL, TC and TG levels, and increasing H-LDL levels.

[0009] Specifically, Xiao Xianxiong Decoction can also reduce the level of aortic MDA, increase the levels of aortic SOD, GSH-Px and GR, and play a role in treating atherosclerosis.

[0010] On the other hand, the present invention also provides a medicine for treating atherosclerosis, the medicine comprising Xiao Xianxiong Decoction, wherein Xiao Xianxiong Decoction comprises Coptis chinensis, Pinellia ternata and Trichosanthes kirilowii, and the mass ratio of Coptis chinensis, Pinellia ternata and Trichosanthes kirilowii is 1:2:5.

[0011] Specifically, the dosage of the drug is 3.139-12.558 g of Xiaoxianxiong Decoction per kilogram of body weight.

[0012] The beneficial effects of the present invention are: The present invention constructs an experimental mouse AS model, studies the effects of Xiaoxianxiong Decoction on the weight of AS mice, the effects of arterial lipid plaques and pathological structures, the effects of liver lipid plaques and pathological structures, the effects of serum blood lipids, and the effects of aortic MDA, SOD, GSH-Px and GR levels, and further explores the mechanism of Xiaoxianxiong Decoction in treating atherosclerosis. Xiaoxianxiong Decoction improves aortic plaques and aortic thickening, improves liver tissue structure, inhibits liver lipid accumulation, reduces serum L-LDL, TC and TG levels, increases H-LDL levels, reduces aortic MDA levels, and increases aortic SOD, GSH-Px and GR levels, thereby playing a role in treating atherosclerosis. The research findings provide a scientific basis for the clinical application of Xiaoxianxiong Decoction. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 The figure is a curve diagram of weight changes of each group of experimental mice in Example 1 of the present invention.

[0014] Figure 2 The results of Oil Red O staining of aorta lipids of each group of experimental mice in Example 2 of the present invention are shown.

[0015] Figure 3 The HE staining results of the aorta of each group of experimental mice in Example 2 of the present invention are shown.

[0016] Figure 4 The lipid Oil Red O staining results of the liver of each group of experimental mice in Example 3 of the present invention are shown.

[0017] Figure 5 The HE staining results of the liver of each group of experimental mice in Example 3 of the present invention are shown.

[0018] Figure 6 These are the test results of serum lipids of each group of experimental mice in Example 4 of the present invention.

[0019] Figure 7 These are the MDA and SOD test results of each group of experimental mice in Example 5 of the present invention.

[0020] Figure 8 These are the GR and GSH-Px test results of each group of experimental mice in Example 5 of the present invention. DETAILED DESCRIPTION

[0021] In order to enable those skilled in the art to better understand the technical solution of the present invention, the technical solution of the present invention is further described below in conjunction with the accompanying drawings and embodiments.

[0022] The Trichosanthes kirilowii (batch number: 20210301), Pinellia ternata (batch number: 20210701), and Coptis chinensis (batch number: 20210401) used in all embodiments of the present invention were purchased from Shaanxi Xingshengde Co., Ltd. and identified as genuine by Associate Researcher Chen Zhiyong of Shaanxi Institute of Traditional Chinese Medicine. Unless otherwise specified, the experimental methods or related detection methods used in the following embodiments adopt methods known in the art. Xiaoxianxiong Decoction is composed of one liang of Coptis chinensis, half a liter of Pinellia ternata, and one large Trichosanthes kirilowii fruit. Example

[0023] In Example 1, a high-fat diet (HFD) was used to construct an AS model in experimental mice. The experimental mice were genetically modified ApoE knockout mice (AopE - / - mouse), AopE - / - Due to lipid metabolism defects, mice accumulate a large amount of cholesterol residues, increase cholesterol levels, and develop into AS, which is one of the common animal models of AS. Wild-type C57 mice served as the control group.

[0024] The specific experimental steps include: (1) Grouping: AopE- / - mice were fed a high-fat diet for 8 weeks and then randomly divided into a model group, a Xiaoxianxiong decoction treatment group (low, medium, and high), and a positive drug group (simvastatin, Siv). C57 mice were fed a normal diet as a control group.

[0025] (2) Drug administration: After 8 weeks of high-fat diet, different groups of experimental mice were given drug treatment (the weight of experimental mice increased significantly after 8 weeks of high-fat diet, indicating successful modeling). The control group and model group were given normal saline, the low-dose group of Xiaoxianxiong Decoction was given Xiaoxianxiong Decoction at 3.139 g / kg, the medium-dose group was given Xiaoxianxiong Decoction at 6.279 g / kg, and the high-dose group was given Xiaoxianxiong Decoction at 12.588 g / kg. The simvastatin positive drug group was given Siv at 0.65 mg / kg, once a day for a total of 8 weeks, ensuring that the time period and method of administration were the same for each administration. During this period, the model group, Xiaoxianxiong Decoction treatment group and positive drug group continued to be fed with a high-fat diet for 8 weeks, and the control group was fed with normal feed.

[0026] (3) During the experiment, the body weight of the experimental mice was observed and recorded once a week, and the changes in body weight of the experimental mice were counted and analyzed.

[0027] The weight changes of experimental mice in different groups are shown in the attached figure. Figure 1 As shown in the attached Figure 1 It can be seen that compared with the control group, the weight of mice in the model group increased, and the weight of mice in the Xiaoxianxiong decoction treatment group and the positive drug group decreased after treatment with Xiaoxianxiong decoction and Siv, indicating that Xiaoxianxiong decoction can reduce the body weight of mice after high-fat diet-induced AS. Example

[0028] Example 2 Based on Example 1, the effect of Xiaoxianxiong decoction on aortic lipid plaque and pathological structure of AS mice was further studied.

[0029] The same experimental grouping and drug administration operation as in Example 1 were used, and then aortic samples of mice in each group were collected, and the changes of aortic lipid plaques were observed by Oil Red O staining, and the changes of aortic pathological structure were observed by HE staining. The specific experimental process includes the following operations: After the experiment in Example 1, the chest and abdominal cavities of each group of mice were opened to expose the heart. The entire length of the aorta was separated along the midline of the chest and abdomen of the mouse, and the excess connective tissue and adipose tissue around the blood vessels were stripped off. The tissues were fixed, dehydrated, and embedded, and then placed on a quick-freezing table for quick freezing. After the cryoembedding agent turned white, continuous sections (5 μm) were made at the root of the aorta using a freezing microtome.

[0030] The aortic sections were stained with Oil Red O staining kit, and the changes of lipid deposition in aortic plaques were observed under a microscope.

[0031] HE staining was performed on the aortic slice samples, and the changes in the aortic pathological structure were observed under an optical microscope. The brief steps of HE staining include placing the aortic pathological slices in xylene for dewaxing, dehydrating with gradient alcohols, transparentizing with xylene, staining with hematoxylin, and finally sealing with neutral gum.

[0032] The results of lipid oil red O staining of aorta of experimental mice are shown in the attached figure. Figure 2 As shown in the attached Figure 2 It can be seen that compared with the control group, obvious red-stained lipids were observed in the aortic gross specimens of mice in the model group, and obvious plaques were observed in the aortic sections; after treatment with Xiaoxianxiong Decoction and Siv, the lipid content in the aortic gross specimens was reduced, and the plaques in the aortic sections were reduced.

[0033] The results of HE staining of the aorta of experimental mice are shown in the attached figure. Figure 3 As shown in the attached Figure 3 It can be seen that the thoracic aorta wall structure of the mice in the control group was clear and normal in morphology, without obvious thickening of the fat wall; the thoracic aorta wall of the mice in the model group was significantly thickened and the structure was incomplete. After Xiaoxianxiong Decoction treatment, the pathological changes such as thickening and incomplete structure of the thoracic aorta wall of the mice were significantly improved. After Siv treatment, the thickness of the thoracic aorta wall of the mice was slightly reduced, but the therapeutic effect was not as significant as that of Xiaoxianxiong Decoction. Example

[0034] Example 3 Based on Example 1, the effect of Xiaoxianxiong Decoction on liver lipid plaques and pathological findings in AS mice was further studied.

[0035] The same experimental grouping and dosing operation as in Example 1 was used, and then liver samples of mice in each group were collected, and the changes in liver lipid plaques were observed by Oil Red O staining, and the changes in liver pathological structure were observed by HE staining. The specific experimental process includes the following operations: After the experiment in Example 1 was completed, the abdominal cavity of each group of mice was opened to obtain the liver tissue of the mice, and the liver tissue was fixed, dehydrated, embedded, etc., and then placed on a quick-freezing table for quick freezing. After the freezing embedding agent turned white, continuous sections (5 μm) were made at the root of the aorta using a freezing microtome, and the sections were sealed with neutral resin, and images were collected under a microscope.

[0036] The liver slice samples were stained with Oil Red O staining kit. The liver tissue was fixed in 4% paraformaldehyde for 48 h, washed with water, embedded in OCT, cooled with dry ice, and frozen. The frozen sections were taken out, washed with ice water, stained with Oil Red O, sealed with glycerol gelatin, dried, and observed under a microscope for image acquisition.

[0037] HE staining was performed on liver slice samples, and the changes in liver pathological structure were observed under an optical microscope. The brief steps of HE staining include placing liver pathological slices in xylene for dewaxing, dehydrating with gradient alcohols, transparentizing with xylene, staining with hematoxylin, and finally sealing with neutral gum.

[0038] The results of HE staining of the liver of experimental mice are shown in the attached figure. Figure 4 As shown in the attached Figure 4It can be seen that the liver cells in the control group were tightly arranged, uniform in size, with large dark nuclei and centered. The model group had obvious adipocyte translocation vacuoles, deformed nuclei, significantly larger cell volume and spacing, loose arrangement, and a large number of inflammatory cell infiltration. After treatment with Xiaoxianxiong Decoction, vesicular steatosis was significantly reduced, and the steatosis was very severe. Inflammation decreased with increasing dosage; in addition, Siv also significantly improved liver lesions and inflammation.

[0039] The results of Oil Red O staining of the liver of experimental mice are shown in the attached figure. Figure 5 As shown in the attached Figure 5 It can be seen that there is no obvious orange-red lipid droplets and lipid deposition in the liver of the control group mice, while the orange-red lipid droplet area and fatty degeneration in the model group increased significantly. Low, medium and high doses of Xiaoxianxiong Decoction treatment improved lipid deposition to varying degrees, and as the dose increased, the improvement in lipid deposition became more obvious; orange-red lipid droplets and lipid deposition in liver tissue also decreased significantly after Siv treatment, indicating that Siv can also improve lipid deposition in the liver. Example

[0040] Example 4 Based on Example 1, the effect of Xiaoxianxiong Decoction on dyslipidemia in AS mice was further studied.

[0041] The same experimental grouping and dosing operation as in Example 1 were used, and then blood samples of mice in each group were collected, and the changes in the levels of H-LDL, L-LDL, TC and TG in the blood of AS mice were detected by a kit. The specific experimental process included the following operations: After the experiment in Example 1 was completed, blood was obtained from mice through the eyelids, and centrifuged at 3500 r / m for 10 min at 4° C. to collect serum for the detection of various blood lipid indicators.

[0042] The test results of various blood lipid indicators of experimental mice are shown in the attached Figure 6 As shown in the attached Figure 6 It can be seen that the H-LDL in the serum of the model group mice was significantly reduced ( P <0.05), L-LDL, TC and TG levels increased significantly ( P <0.05); compared with the model group, the H-LDL in the serum of mice treated with Xiaoxianxiong decoction increased significantly ( P <0.05), L-LDL, TC and TG levels were significantly decreased ( P <0.05); while Siv treatment only increased H-LDL level ( P <0.05). The results showed that Xiaoxianxiong decoction has the effect of improving dyslipidemia during AS. Example

[0043] Example 5 Based on Example 1, the effect of Xiaoxianxiong decoction on the levels of MDA, SOD, GSH-Px and GR in AS mice was further studied.

[0044] The same experimental grouping and drug administration procedures as in Example 1 were used, and then aorta samples of mice in each group were collected, and the changes in the levels of MDA, SOD, GSH-Px and GR in the aorta of AS mice were detected by a kit. The specific experimental process included the following operations: After the experiment in Example 1 was completed, aorta samples from each group of experimental mice were collected, and the samples were ground using a tissue grinder, followed by tissue protein extraction, and the protein concentration was determined using a BCA protein quantification kit, and finally the MDA, SOD, GR and GSH-Px levels were detected using a kit.

[0045] The test results of MDA and SOD in experimental mice are shown in the attached Figure 7 The detection results of GR and GSH-Px are shown in the attached Figure 8 As shown. Figure 7 and attached Figure 8 It can be seen that compared with the control group, the MDA level in the aorta samples of the model group mice increased significantly ( P <0.05), the levels of SOD, GSH-Px and GR were significantly decreased (P<0.05); compared with the model group, the level of MDA in the aorta samples of mice treated with Xiaoxianxiong decoction was significantly decreased ( P <0.05), the levels of SOD, GSH-Px and GR increased significantly ( P <0.05); however, after Siv treatment, the MDA level was significantly decreased (P<0.05), and the GR level was increased ( P <0.05), but Siv treatment had no significant effect on SOD and GSH-Px ( P >0.05).

[0046] In summary, Xiaoxianxiong Decoction can reduce the body weight of mice with atherosclerosis induced by a high-fat diet, improve aortic plaques and aortic thickening in mice, improve liver tissue structure, inhibit liver lipid accumulation, reduce serum low-density lipoprotein, triglyceride, and total cholesterol levels, and increase high-density lipoprotein levels. In addition, Xiaoxianxiong Decoction can also reduce the level of malondialdehyde (MDA) in the aorta of mice with atherosclerosis, increase the levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and glutathione reductase (GR), and is expected to be used as a drug component for the treatment of atherosclerosis. Example

[0047] Embodiment 6 provides a medicine for treating atherosclerosis, the medicine includes Xiao Xianxiong Decoction (it may also include other auxiliary materials, which are not limited in the invention), Xiao Xianxiong Decoction includes Coptis chinensis, Pinellia ternata and Trichosanthes kirilowii, and the mass ratio of Coptis chinensis, Pinellia ternata and Trichosanthes kirilowii is 1:2:5.

[0048] The dosage of the drug is 3.139-12.558 g of Xiaoxianxiong Decoction per kilogram of body weight.

[0049] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. Application of Xiaoxianxiong Decoction in the preparation of medicines for treating atherosclerosis.

2. The use according to claim 1, characterized in that: The components of the Xiao Xianxiong Decoction include Coptis chinensis, Pinellia tuber and Trichosanthes fruit.

3. The use according to claim 1, characterized in that: Xiao Xianxiong Decoction plays a role in treating atherosclerosis by improving aortic plaques and aortic thickening, improving liver tissue structure, inhibiting liver lipid accumulation, lowering serum L-LDL, TC and TG levels, and increasing H-LDL levels.

4. The use according to claim 3, characterized in that: Xiao Xianxiong Decoction can also reduce the level of aortic MDA, increase the levels of aortic SOD, GSH-Px and GR, and play a role in treating atherosclerosis.

5. A drug for treating atherosclerosis, characterized in that: The medicine includes Xiao Xianxiong Decoction, wherein Xiao Xianxiong Decoction includes Coptis chinensis, Pinellia ternata and Trichosanthes kirilowii, and the mass ratio of Coptis chinensis, Pinellia ternata and Trichosanthes kirilowii is 1:2:

5.

6. A drug for treating atherosclerosis according to claim 5, characterized in that: The dosage of the drug is 3.139-12.558 g of Xiaoxianxiong Decoction per kilogram of body weight.

Citation Information

Patent Citations

  • Compound traditional Chinese medicine preparation with effect of atherosclerotic plaque regression and reversal

    CN103623189A

  • Decocting technique of Xiaoxianxiong decoction

    CN103656011A

  • Ultra-high performance liquid chromatography-mass spectrometry detection method for in-vivo and in-vitro components of classic famous prescription Xiaoxiaoxiao decoction

    CN117805280A